Concept Life Sciences and OpenBench have formed a strategic alliance aimed at enhancing hit identification for biotech firms through an innovative fee-for-success model.
This partnership merges OpenBench's AI-driven, structure-based discovery platform with Concept Life Sciences' expertise in medicinal chemistry and in-vitro screening. The collaboration promises to expedite the journey from target identification to validated hit series, potentially within a six-month timeframe. OpenBench's model allows for initial screening and research to be conducted at their own expense, significantly reducing the financial burden on clients until validated hits are achieved.
Concept Life Sciences will leverage its comprehensive 'design-make-test' capabilities to further enhance the partnership, facilitating quicker advancement of promising candidates toward clinical development across various therapeutic areas. This integrated approach is particularly crucial in today's challenging funding landscape, where biotechs are seeking more efficient and lower-risk pathways to viable chemical starting points.
The collaboration underscores a growing trend in the life sciences sector, where reducing upfront costs and uncertainties in early discovery is essential for fostering innovation. By aligning their strengths, Concept Life Sciences and OpenBench are poised to deliver a streamlined process for biotech companies, ultimately accelerating the pace of drug discovery and development.